_{Our Laboratory Services & Test Offerings}

Comprehensive Neurogenetic (203 Genes) Panel for Precision Medicine. Target Exome Panel for Epilepsy, Neuromuscular & Neurodegenerative Disorders.

*Insurance accepted pending eligibility verification and/or prior authorization.

Neurodevelopmental & Autism Spectrum Disorders Panel (338 Genes) for Precision Medicine: A Targeted Exome Panel for Hereditary Neurodevelopmental and Autism Spectrum Conditions

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Hereditary Cancer Panel (116 Genes) for Precision Medicine - Targeted Exome Panel for Inherited Cancer Predisposition and Tumor Risk Assessment

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Immunogenetic Panel (291 Genes) for Precision Medicine A Targeted Exome Panel for Hereditary Immunology Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

Cardiovascular & Pulmonary Disorders Panel (232 Genes) for Precision Medicine: A Targeted Exome Panel for Inherited Cardiopulmonary Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Metabolic Disease Panel (533 Genes) for Precision Medicine: A Targeted Exome Panel for Inherited Metabolic Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Kidney Disease Panel (153 genes), for Inherited Chronic Kidney Disease, Glomerular Disorders, Tubulopathies & Cystic Kidney Disease

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Hereditary Hearing Loss Panel (137 genes) – A Targeted Exome Panel for Congenital and Late-Onset Hearing Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Ocular Disease Panel (331 genes) – A Targeted Exome Panel for Inherited Retinal Disease, Optic Neuropathy, Corneal/Lens Disorders, and Glaucoma-Related Syndromes

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Connective Tissue Disorder Panel (84 genes) – A Targeted Exome Panel for Heritable CTDs

*Insurance accepted pending eligibility verification and/or prior authorization.

Comprehensive Carrier Panel (333 Genes Females, 281 genes males) for Precision Medicine – A Targeted Exome Panel for Heritable Conditions

*Insurance accepted pending eligibility verification and/or prior authorization.

Female Infertility & Reproductive Health Panel (72 Genes) for Precision Medicine – A Targeted Exome Panel for Hereditary Female Infertility and Reproductive Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

Male Infertility & Reproductive Health Panel (68 Genes) for Precision Medicine – A Targeted Exome Panel for Hereditary Male Infertility and Reproductive Disorders

*Insurance accepted pending eligibility verification and/or prior authorization.

A US FDA–approved, kitted solution for comprehensive genomic profiling, The test interrogates both DNA and RNA from FFPE tissue.

*Insurance accepted pending eligibility verification and/or prior authorization.

PharmacoCheck+ enables precision prescribing by identifying genetic risks for adverse drug reactions and treatment failure. This fast, cost-effective tool supports safer, more personalized care—helping clinicians optimize therapy based on each patient’s genetic profile.

*Insurance accepted pending eligibility verification and/or prior authorization.

Multiplex PCR Panel from PreCheck Health Services provides a rapid, reliable, and clinically relevant diagnostic tool to guide treatment, limit viral spread, and improve outcomes in patients with respiratory symptoms. This panel is critical in both community and institutional settings to ensure timely and appropriate care.

*Insurance accepted pending eligibility verification and/or prior authorization.

The UTI PCR Panel offered by PreCheck Health Services delivers rapid, comprehensive, and clinically relevant results for effective UTI management. With its broad pathogen coverage, antibiotic resistance profiling, and fast turnaround, it is an essential tool for modern urologic and infectious disease care. This panel improves diagnostic accuracy, enables timely therapy, and supports responsible antibiotic use.

*Insurance accepted pending eligibility verification and/or prior authorization.